Managing the Unmanageable: A Two-Staged Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent Paraganglioma by Smucker, Levi Y. et al.
Received: 2017.10.26
Accepted: 2017.12.28
Published: 2018.04.02
 1573   —   3   8
Managing the Unmanageable: A Two-
Staged Palliative Resection to Control Life-
Threatening Duodenal Bleeding Due to Recurrent 
Paraganglioma
 AEF 1,2 Levi Y. Smucker
 A 2,3 Ashley N. Hardy
 A 3 Peter J. O’Neil
 ABE 1,2,3 Roderich E. Schwarz
 Corresponding Author: Roderich E. Schwarz, e-mail: RSchwarz@goshenhealth.com
 Conflict of interest: None declared
 Patient: Male, 40
 Final Diagnosis: Paraganglioma
 Symptoms: GI bleeding • syncope
 Medication: —
 Clinical Procedure: Palliative multivisceral staged resection
 Specialty: Surgery
 Objective: Unusual clinical course
 Background: This report presents therapeutic decision-making and management of refractory, life-threatening duodenal 
bleeding in a young man with recurrent metastatic retroperitoneal paraganglioma.
 Case Report: The patient had been symptom free for 8 years after radioactive MIBG (metaiodobenzylguanidine) therapy. 
Failure of endoscopic or angiographic bleeding control led to urgent need to evaluate possible endocrine func-
tional status, tumor curability, safety of incomplete resection, intra- and postoperative support needs, and an-
ticipated recovery potential and postoperative function. Aside from these considerations, impact of tumor bi-
ology, alternative therapeutic options, current management guidelines, and ethical challenges of resource 
utilization for such complex palliative operative intervention were reviewed.
 Conclusions: Based on the observed outcomes after an urgent presentation of an unusual tumor-related complication, pal-
liation-intent therapy was justifiable even if significant treatment-related risks were expected and complex re-
sources were required.
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Background
Life-threatening duodenal bleeding that remains refractory to 
endoscopic or interventional radiologic management has be-
come a relatively uncommon clinical scenario that provides 
significant therapeutic challenges. While primary gastrointes-
tinal (GI) or vascular conditions represent the most common 
underlying mechanisms for such problem, duodenal hemor-
rhage as a result of primary, recurrent, or metastatic paragan-
glioma is exquisitely rare [1]. We encountered a paraganglio-
ma-related duodenal bleed that required urgent and complex 
therapeutic decisions.
Case Report
A 40-year-old male presented with a massive upper GI bleed. 
Cross-sectional imaging and esophagogastroduodenoscopy 
(EGD) revealed a large mass eroding into the duodenum, refrac-
tory to endoscopic hemostasis. Two attempts at interventional 
radiologic hemostasis (arterial embolization and endovascular 
coiling) were undertaken and failed. Ten years prior to pre-
sentation the patient had been diagnosed with succinate de-
hydrogenase-B (SDHB) mutant metastatic paraganglioma. He 
subsequently had been treated twice with radioactive 131Iodine-
metaiodobenzylguanidine (MIBG) therapy, with an initial com-
plete response. He subsequently remained asymptomatic and 
was thus lost to follow-up for 8 years. After failed non-operative 
management and after 2 independent surgical consultations that 
deemed this tumor process to be technically unresectable, the 
patient was transferred to our hospital. He had received 12 units 
PRBC transfusions in the prior 4 days. Upon admission, he was 
in no current distress and hemodynamically stable. Computed 
tomography imaging revealed a large retroperitoneal primary 
tumor and several small bony metastases. The 18×16×13 cm 
mass that extended between liver hilum and aortoiliac bifur-
cation, exhibited central necrosis, high vascularity, and duode-
nal involvement, and was accompanied by 5 small peritoneal 
nodules (Figure 1). Vascular structures in the hepatoduodenal 
ligament were displaced but not encased, and the infrahepat-
ic inferior vena cava (IVC) was not visualized. Laboratory values 
included a hemoglobin concentration of 9.4 g/dL, international 
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Figure 1.  Computed tomography images. (A) Highest extent of the tumor (arrow). (B) Superior mesenteric artery origin (arrow). 
Tumor mass with 3 endovascular coiling artifacts. Note the absence of a continuous contrast column within the area of the 
inferior vena cava. (C) Tumor involvement of the duodenum (arrow); the mesenteric root to the right is not directly involved. 
(D) Lowest extent of the main tumor, with additional adjacent tumor nodule (arrow).
387
Smucker L.Y. et al.: 
Managing the unmanageable…
© Am J Case Rep, 2018; 19: 386-391
Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)]
[Web of Science by Clarivate]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
normalized ratio (INR) of 1.3, and mildly elevated plasma norepi-
nephrine (641 pg/mL) and normetanephrine (1.21 nmol/L) lev-
els. Plasma epinephrine and dopamine levels, and the vanillyl 
mandelic acid (VMA)/creatinine ratio were within normal limits.
Operative therapy
With the goal to palliate this life-threatening bleed, operative 
preparations were made. The team was prepared to resect and 
reconstruct portions of duodenum, IVC, liver, or pancreas as 
necessary. Intraoperatively, a large, firm, and fixed mass was 
encountered, which involved the second and third portions of 
the duodenum but appeared to be displacing common hepat-
ic artery (CHA), superior mesenteric vein (SMV), portal vein 
(PV), and superior mesenteric artery (SMA) (Figure 2). Figure 3 
provides schematic outlines of the intraoperative images in 
Figure 2. After lengthy and challenging development of peri-
pancreatic, infrahepatic, and posterior tumor planes, safe re-
section required committing to pancreatoduodenectomy. Thus, 
the gastroduodenal artery (GDA) was divided, and bile duct, 
gastric antrum, and pancreatic neck were transected, allowing 
for further mobilization. The most difficult plane remained pos-
terior to the tumor and at the inferolateral liver edge, where 
significant radiation fibrosis and challenging bleeding were en-
countered. After 12 hours of operating time, the patient be-
came coagulopathic and acidotic, and the decision was made 
for temporary packing and resuscitation prior to a possible sec-
ond attempt at resection. At this time point, the patient had 
been transfused with 10 units of PRBCs for an estimated blood 
loss of 8.2 L. After overnight stabilization and correction of the 
acidotic state, the patient underwent successful completion of 
mass resection, albeit in form of R2 resection, with en bloc pan-
creatoduodenectomy, followed by anastomotic reconstruction.
Hospital course
The patient had an uneventful postoperative course until post-
operative day 11 when a GDA stump bleed was encountered 
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Figure 2.  Intraoperative images. (A) First operation: initial appearance of the infrahepatic mass. (B) First operation: relationship 
between peritumoral tissues and superior mesenteric vein (SMV, arrow). (C) Second operation: dissection plane between 
tumor and hepatic artery (1), and at pancreatic neck (2). (D) Second operation: appearance after completed R2 resection.
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and successfully controlled by angiographic stenting. He was 
discharged on postoperative day 27, tolerating a regular diet. 
Currently he is symptom-free, with very good performance sta-
tus, at 8 months after the resection. He has started oral cyto-
toxic therapy with the intent to provide some control benefit 
of his residual tumor.
Discussion
An unusual combination of a rare disease mechanism, acute 
and threatening presentation, complex operative therapy re-
quirements, and system challenges all were felt to be of great 
impact in this case, and deserve to be highlighted and dis-
cussed in more detail.
The rate of metastatic disease in paragangliomas, often re-
ferred to as extra-adrenal pheochromocytomas, has been re-
ported to be around 10% [1]. Lifelong follow-up is recommended 
especially for young patients, for those with germline muta-
tions (such as SDHB), for extra-adrenal tumors, and for large 
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Figure 3.  (A–D) Schema for intraoperative findings as displayed in Figure 2.
tumor size [2]. Malignant paragangliomas are more common 
in carriers of the SDHB mutation [3]. Prognosis is worse in the 
metastatic setting, with an overall 5-year survival of less than 
50% [4]. The mainstay of treatment at this stage is systemic 
therapy, including the aforementioned 131I MIBG therapy, or the 
more recently validated peptide receptor radionuclide thera-
py that has been associated with some overall survival ben-
efit [5]. Symptoms due to localized disease may benefit from 
specific local therapy options including resection.
Given such a relatively rare disease entity, which aspects were 
supportive of an operative intervention in this particular case? 
This resection, with a truly “palliative” intent for symptom con-
trol, actually saved a patient from ongoing hemorrhage and re-
sulting death. Interventional radiologic procedures had failed, 
leaving laparotomy and resection as the only sensible remain-
ing option. It was clear that the operation would not be cura-
tive, but that the somewhat favorable biology of this tumor 
would possibly support some significant quality life after suc-
cessful recovery. Indeed, in some select circumstances of slow-
growing malignant tumors, even palliative R2 resections can 
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confer some survival advantage, through controlling symptoms 
and thus facilitating additional treatment options [6]. For most 
paragangliomas, as in this case, the relative oncologic hazard 
appears to be lesser, and the size or functional status of the 
tumor have not been shown to affect survival [4].
How safe was this resection? Paragangliomas can exhibit en-
docrine function approximately 50% of the time [4]. However, 
this tumor was deemed non-functional since the patient had 
no related hemodynamic abnormality, and since there was 
no meaningful serum elevation of any vasoactive compound. 
Consequently, there was no intraoperative need for specific 
pharmacologic control of vasoactive hormone effects. The tu-
mor was highly vascular, but the CHA, PV, SMA and SMV were 
not encased while the IVC was expected to be possibly involved. 
While involvement of a large vascular structure is not an ab-
solute contraindication to resection, the resulting reconstruc-
tion challenges, greater morbidity risks and thus reduced pal-
liation benefit would require a very cautious selection of such 
a step. In addition, the availability of transfusion products and 
the proper hemodynamic support must be stressed as essen-
tial intraoperative components for successful management.
Which operative steps defined key challenges in this case? In 
the first operation, the team had to commit to a pancreato-
duodenectomy before complete tumor mobilization because 
further dissection progress did not appear possible without 
transection of the visceral structures involved. This operative 
decision and implicit commitment to en bloc resection neces-
sitates anastomotic reconstruction for any meaningful recov-
ery. Another difficult step was deciding to abort the first oper-
ation. While this staged approach is more commonly utilized in 
trauma settings, the patient acuity for surgical oncology pro-
cedures rarely leads to the need to “stabilize in the interim”. 
It proved necessary, and against initial expectations, was suc-
cessful in this case. Finally, deciding when to proceed with the 
second operative step and whether to consider an immediate 
reconstruction after mass removal was based on the patient’s 
recovery in terms of hemodynamics and acidosis overnight, 
and the relative stability encountered during the second-stage 
completion of resection. A possible third-step procedure for 
reconstruction was not expected to be superior to an imme-
diate reconstruction decision.
Surgical palliation is still a challenging concept, even within 
surgical oncology, and there is a lack of consensus if palliation 
is defined by intent, postoperative factors, or prognosis [7]. 
Symptom resolution, patient age, and gained quality-of-life 
years are all validated reasons that can support this opera-
tion [8]. Our patient was young, his bleeding resolved as a re-
sult of the procedure, and he gained quality time with a cur-
rent excellent postoperative performance status. A central 
problem was of course the difficulty in predicting any mean-
ingful longer-term success that could be achieved with such 
radical and complex therapy. A similar palliation decision had 
to be made at the time of postoperative GDA bleeding, with 
uncertain efficacy and outcomes of an interventional radio-
graphic procedure. If physicians are involved in any compa-
rable clinical scenario, the balance between difficult life-pre-
serving efforts, the desire for compassionate individual patient 
support, and facing the uncertainty of an incurable malignan-
cy is expected to always be challenging. In addition, the ethi-
cal dilemma around the appropriateness of utilizing resourc-
es in such a situation, both institutional (blood bank support, 
blood transfusion products) and societal (spending of health 
care resources, post-hospital support), needs to be carefully 
contemplated and weighed against anticipatable intervention 
benefits. The presented case of our patient’s outcomes appear 
to represent a more successful and hopefully instructive ex-
ample for such balanced decision-making.
Conclusions
Retroperitoneal paragangliomas are rare, slow-growing tu-
mors with potential for metastasis and endocrine function. 
A slow course of disease progression can lead to significant 
symptoms that are caused by local tumor invasion. As the pre-
sented case highlighted, palliative resection is indicated in the 
younger, more functional patient with significant tumor-relat-
ed symptoms and lack of less invasive options, even in the set-
ting of metastatic disease. Complex multivisceral resection as 
described requires proper expertise and resources to conduct 
safe (possibly staged) operations, complex anesthesia, vascu-
lar control and appropriate perioperative patient management. 
Aside from the primary intent of life-preserving therapy, it is 
also anticipated that successful palliation can enable the pa-
tient to undergo additional tumor-directed therapy, with a po-
tential for further progression-free survival benefits.
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